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De novo and rare inherited copy-number variations in the
hemiplegic form of cerebral palsy
Mehdi Zarrei, PhD1,14, Darcy L. Fehlings, MD2,14, Karizma Mawjee, MA2, Lauren Switzer, MSc2,
Bhooma Thiruvahindrapuram, MSc1, Susan Walker, PhD1, Daniele Merico, PhD1,3,
Guillermo Casallo, BSc1, Mohammed Uddin, PhD1, Jeffrey R. MacDonald, BSc1,
Matthew J. Gazzellone, MSc1, Edward J. Higginbotham, BSc1, Craig Campbell, MD4,
Gabrielle deVeber, MD5, Pam Frid, MD6, Jan Willem Gorter, MD7, Carolyn Hunt, MD8,
Anne Kawamura, MD2, Marie Kim, MD9, Anna McCormick, MD10, Ronit Mesterman, MD7,
Dawa Samdup, MD11, Christian R. Marshall, PhD1, Dimitri J. Stavropoulos, PhD12,
Richard F. Wintle, PhD1 and Stephen W. Scherer, PhD1,13
Purpose: Hemiplegia is a subtype of cerebral palsy (CP) in which
one side of the body is affected. Our earlier study of unselected
children with CP demonstrated de novo and clinically relevant rare
inherited genomic copy-number variations (CNVs) in 9.6% of
participants. Here, we examined the prevalence and types of CNVs
specifically in hemiplegic CP.
Methods: We genotyped 97 unrelated probands with hemiplegic
CP and their parents. We compared their CNVs to those of 10,851
population controls, in order to identify rare CNVs (o0.1%
frequency) that might be relevant to CP. We also sequenced exomes
of “CNV-positive” trios.
Results: We detected de novo CNVs and/or sex chromosome
abnormalities in 7/97 (7.2%) of probands, impacting important
developmental genes such as GRIK2, LAMA1, DMD, PTPRM, and
DIP2C. In 18/97 individuals (18.6%), rare inherited CNVs were
found, affecting loci associated with known genomic disorders
(17p12, 22q11.21) or involving genes linked to neurodevelopmental
disorders.
Conclusion: We found an increased rate of de novo CNVs in the
hemiplegic CP subtype (7.2%) compared to controls (1%). This
result is similar to that for an unselected CP group. Combined with
rare inherited CNVs, the genomic data impacts the understanding
of the potential etiology of hemiplegic CP in 23/97 (23.7%) of
participants.
Genet Med advance online publication 3 August 2017
Key Words: copy-number variation; exome sequencing; hemiplegic
cerebral palsy; microarray
INTRODUCTION
Cerebral palsy (CP) is a permanent and nonprogressive
condition that impacts posture and movement, affecting 2.0–
3.5 per 1,000 live births.1 CP is a complex syndrome that can
be defined and classified according to functional ability,
topographical involvement of extremities, and neurologic
patterns (spasticity, dyskinesia, and ataxia).1 The common
neurological topography within the spastic subtype includes
hemiplegia, quadriplegia, and diplegia.1 The Gross Motor
Function Classification System (GMFCS) assesses functional
motor ability, with levels from I (walks without limitations) to
V (transported in a wheelchair).2
Hemiplegic CP is a subtype in which one side of the body is
involved.3 It affects about 1 in 1,300 live births.3 This CP
subtype accounted for 37.4% of CP cases in a Canadian cohort
previously studied by our team.4 The etiology of hemiplegic
CP is most commonly related to a unilateral vascular insult
often involving the middle cerebral artery, a periventricular
venous infarction, or a unilateral brain malformation (e.g.,
schizencephaly).5 When the injury is vascular in origin
porencephaly can also be identified on brain imaging. Motor
function is impaired in the body contralateral to the brain
injury/anomaly. Individuals with hemiplegic CP generally are
able to ambulate and function at a GMFCS level of I or II.
Along with movement and posture anomalies, CP can
involve comorbidities, including seizure disorders, speech and
language deficit, autism spectrum disorder (ASD), intellectual
disability (ID), visual impairment, and hearing problems.1
1The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada; 2Holland Bloorview Kids
Rehabilitation Hospital, Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada; 3Deep Genomics Inc., Toronto, Ontario, Canada; 4Department of Pediatrics,
Schulich School of Medicine, Western University, London, Ontario, Canada; 5Division of Neurology, Department of Pediatrics, Hospital for Sick Children, University of Toronto,
Toronto, Ontario, Canada; 6Thames Valley Children’s Centre, London, Ontario, Canada; 7McMaster University, Hamilton, Ontario, Canada; 8Grandview Children’s Centre,
Oshawa, Ontario, Canada; 9ErinoakKids Centre for Treatment and Development, Mississauga, Ontario, Canada; 10Ottawa Children’s Treatment Centre, Ottawa, Ontario, Canada;
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Multiple risk factors are associated with CP, including the
hemiplegic subtype. For example, neonatal asphyxia is
thought to be a cause of related brain damage accounting
for approximately 10–20% of cases.1
As with other neurodevelopmental disorders, genes have
increasingly been found to have a role in the etiology of CP.
However, the genetic findings in CP are heterogeneous,
making it difficult to use them diagnostically.4 Twin and
family studies have found that variations in genes encoding
the AP-4 complex (AP4M1, AP4E1—also with an exonic
deletion, AP4B1, and AP4S1)6,7 and KANK1 are associated
with CP.8 Large chromosomal anomalies were detected in 8%
of individuals in a cohort of 100 Japanese CP cases, tested
using karyotyping.9 In a cohort of 50 cases from the South
Australia CP registry, genome-wide copy-number variation
(CNV) studies showed that CP was associated with rare
inherited CNVs.10 Both rare and de novo CNVs were found
associated with CP in 52 cases from Israel.8 A small study of
71 Japanese individuals with porencephaly or schizencephaly
screened specifically for COL4A1 variations and identified a
variation in 15 (21%).11 Five of these individuals had a
diagnosis of hemiplegic CP. Our previous study of 147
Canadian cases with parents, comprising different CP
subtypes (including 37.4% with hemiplegia) revealed de novo
CNVs in 7% of cases.4 We also found multiple large
chromosomal anomalies and rare inherited variants in CP
cases.4,12
In the present study our objective was to assess the role of
CNVs and chromosomal abnormalities in a clinically well-
defined collection of individuals with hemiplegic CP to
further refine the understanding of the genomic risk
contribution in this common subtype of CP.
MATERIALS AND METHODS
Participants
Ninety-seven children diagnosed with hemiplegic CP (aged
2–18 years, mean= 9.35, SD= 4.9) were recruited and studied
here for the first time. This cross-sectional study was
conducted through the Childhood Hemiplegic Cerebral Palsy
Integrated Neuroscience Discovery Network (CP Hemi-NET)
spanning nine clinical centers across Ontario, Canada.
Research Ethics Board approval was obtained from each
center and all caregivers and participants (if able) provided
written informed consent. Saliva samples were collected from
each child and birth parents.
Measures
Clinical risk factors
A retrospective health record review and a standardized
parent interview identified pre-conception, pregnancy, and
perinatal–neonatal CP risk factors. Examples of potential risk
factors included prematurity, advanced maternal age, in vitro
fertilization, congenital malformations, consanguinity, and a
family history of CP or early stroke or heart attack at younger
than 55 years. Markers of childbirth complications were also
identified and pooled and included emergency C-section,
Apgar score o6, resuscitation at birth, umbilical cord blood
pH o7.35, seizures in the first 24 to 72 h of life, or neonatal
encephalopathy.
Clinical outcomes
An occupational therapist evaluated the side of the hemiplegia
and unilateral hand skills in the child’s hemiplegic hand using
the Quality of Upper Extremity Skills Test (QUEST).13
QUEST scores range from 0 (no ability to use hand) to 100
(typical hand skills). GMFCS levels were obtained from the
health record. Clinically ordered neuroimaging exams were
reviewed for brain injury/anomaly classification. The neuro-
developmental profiles were evaluated using previously
completed clinical psychoeducational assessments including
IQ scores where available. Clinical diagnoses such as attention
deficit/hyperactivity disorder (ADHD), ASD, and learning
and intellectual disabilities were noted from the psychology or
health record. A summary of the CP risk factors and clinical
outcomes for a selected number of CNV-positive cases is
found in Supplementary Table S1 online.
Genotyping and variant calling
Genomic DNA extracted from saliva was genotyped on the
Affymetrix CytoScan HD platform at The Centre for Applied
Genomics.4 Relevant microarray data are deposited in the
Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/
geo/; GSE80813). The quality control and ancestry assessment
procedures were as discussed previously.4 The ancestry of
samples was determined using PLINK v1.90b2, finding 67
families of European ancestry, and 30 from other back-
grounds (Supplementary Table S2).
We called CNVs as previously described (Supplementary
Information). The genomic coordinates used are based on
Human Genome Build GRCh37/hg19.
Detection of rare variants
We identified rare CNVs as those at not more than 0.1%
frequency among 10,851 population control samples
(Supplementary Figure S1), using a 50% reciprocal overlap
strategy.14 We further restricted our list to those with more
than 75% overlap with copy-number stable regions, according
to our stringent CNV map of the human genome (see
Supplementary Information).15 CNVs deemed relevant, as
indicated below, were validated using an SYBR Green-based
real-time quantitative PCR assay, TaqMan Copy Number
Assays, or droplet digital PCR (ddPCR) (Supplementary
Table S3).
Brain-expressed critical exons and burden of pLI scores
We tested the burden of critical exons as identified by Uddin
et al.16 in genes whose coding sequences were impacted by
rare CNVs, in cases compared with controls, for 16 different
brain regions (see Supplementary Information). We
performed our analyses at three developmental time points:
prenatal (12–37 weeks of gestation), early postnatal and
adolescence (4 months–15 years) and adult (>18 years).
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We also obtained the probability of truncating loss-of-
function intolerance (pLI)17 for genes impacted by deletions
in our cases compared with all 10,851 control subjects at the
individual level. We compared cases to controls using an
unpaired t-test between sums of pLI scores in cases compared
with controls to evaluate significance in genetic burden.
Exome sequencing
We undertook exome sequencing to search for potential
smaller sequence-level variants not found by microarrays in
the 23 families with CNV findings most relevant to CP
(Table 1). Our rationale was to investigate whether additional
mutations identified might help explain the hemiplegic CP
itself or some other medical comorbidity. Exome sequencing
was conducted using the Illumina HiSeq2500 at the Centre for
Applied Genomics. Sequencing data analysis, alignment,
variant calling, and filtering were as described previously.18
We investigated damaging variants and those impacting
genes previously implicated in neurodevelopmental or
neuromuscular disorders.
RESULTS
Our hemiplegic cohort had a sex ratio of 1.5 (59 male: 38
female subjects), which is slightly higher than that reported
from the general CP population (1.3).19 There was a balanced
distribution of left (52.6%) and right (47.3%) hemiplegia. The
mean QUEST score was 64 (SD= 29.5) and GMFCS levels
ranged from I to III with a median level of I.
We detected 340 stringent CNVs in proband DNA
(Supplementary Table S2). These ranged from 10 kb to a
duplication of the entire X chromosome. The majority of
CNVs were deletions (n= 222; 65%) and 118 were
duplications (35%). Of these, 129 (38%) affect coding
sequences of genes, and 62% involved noncoding regions of
the genome.
Clinically relevant variants
In 23 individuals, 30 CNVs with potential relevance to CP
were identified (Table 1). These CNVs were either de novo
(nine events in seven cases), or involved regions associated
with known DECIPHER syndrome loci or ClinGen loci (three
cases; one de novo and two paternally inherited), impacted a
gene with an established disease role in the brain or muscle, or
involved in ASD or comorbid features of CP such as seizure
or hearing loss (19 events in 16 cases).
We identified de novo CNVs in 7/97 (7.2%) patients. These
included a CNV congruent with the steroid sulfatase
deficiency DECIPHER syndrome locus, and one instance of
Klinefelter syndrome (XXY chromosomes; Table 1). We
identified two patients each with two different de novo CNVs.
Case B had a 70.4 Mb duplication encompassing the whole p
arm and part of the q arm of chromosome X, and a deletion of
the rest (84.9 Mb) of the q arm (Turner syndrome). This
70.4 Mb duplication was confirmed to be mosaic by ddPCR.
The other, Case D, carried a duplication in 18p11.23–
18p11.31, impacting three genes—LAMA1, PTPRM, and
LRRC30—and a duplication in Xp21.2 impacting the DMD
gene (Figure 1). We also found a 67.6 kb mosaic deletion
impacting at least two exons of the DIP2C gene in two
unrelated cases (cases F and G). In addition, we observed a de
novo deletion impacting the same segment (at least two
exons) of this gene in a case first reported in our previous
publication.4 We validated this deletion and refined its
boundaries in those three cases using eleven different
TaqMan assays by ddPCR (see Supplementary Information
for experiments performed on these three cases). Genotype
data suggest this deletion may be somatic in origin,
necessitating testing in additional tissues for confirmation.
Of 21 rare inherited CNVs, 14 were inherited maternally
and seven paternally. Two of the latter involved DECIPHER
syndrome loci: 22q11.2 duplication syndrome (case G;
Figure 1) and hereditary neuropathy with liability to
pressure palsies syndrome (case H). Of the remaining
inherited CNVs, 12 were duplications and 7 were deletions.
Critical exons and pLI scores
We observed an enrichment of brain critical exons among
CNVs in cases compared with the platform-matched controls
(see Supplementary Information). The difference was
significant (Po0.05) for exons with prenatal expression in
16 brain regions, whereas only amygdaloid complex,
cerebellar cortex, and primary motor cortex showed such a
difference in the exons with expression from childhood to
adolescence (Figure 2). CNVs in CP cases were enriched for
exons expressed in adults in these regions.
Mean pLI scores were higher, but not statistically
significant, in our cases compared with controls genotyped
on platforms other than CytoScan HD (0.267 vs. 0.096;
P= 0.109) and with platform-matched controls (0.267 vs.
0.10; P= 0.118).
Exome sequencing
We found 30 de novo variants from 17 cases (Supplementary
Table S4). We identified potential risk variants in two cases.
Case E has a nonsynonymous de novo single nucleotide
variant (SNV) in ENTPD1, which is recessive and involved in
spastic paraplegia (OMIM 615683). This case also carries a
nonsynonymous de novo SNV in NOVA1, a Nova-family
RNA-binding protein, important for splicing regulation in
neurons, predicted to be haploinsufficient (pLI= 0.98), and
resulting in motor dysfunction when knocked out in mouse
(OMIM 602157). The second case, Case L, has a nonsynon-
ymous de novo SNV in ATAD3C, also involved in various
neurological disorders.20 We also found 45 rare inherited
SNVs impacting the neurodevelopmental or neuromuscular
disorders from 21 cases. We additionally identified two
different damaging missense variants in COL4A2, which is
involved in muscular disorders (OMIM 120090), inherited
from the mother of case G (Figure 1) and from the father of
case Q.
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Table 1 Copy-number variations of potential significance in 23 CP subjects
Casea ID Sex Typeb Location Size (bp)c Genesd Inheritance CNV pathogenicity Neurodevelopmental profilee
De novo
Case Af 200117 M dup Xp22.33–Xq28 155,270,560 826 genes De novo Pathogenicg Normal intellectual development
Case Bh 234968 F del Xq13.1–Xq28 84,886,227 457 genes De novo Pathogenici N/A
dupj Xp22.33–Xq13.1 70,384,332 369 genes De novo Pathogenic
Case Cf 212306 F del Xp22.31 1,686,421 STS + 4 genes De novo VOUSk Normal intellectual development
dup 11q24.1 76,847 SCN3B, GRAMD1B Maternal VOUS
dup 3q11.2 39,636 EPHA6 Maternal VOUS
Case Dh 208937 F dup 18p11.23, 18p11.31 1,146,375 LAMA1, PTPRM, LRRC30 De novo VOUS Language-based learning disability
dup Xp21.2 309,376 DMD, FTHL17 De novo VOUSl
Case Ef 216072 F del 6q16.3 475,077 GRIK2 De novo VOUSm Normal intellectual development
Case Ff 216185 M delj 10p15.3 67,632 DIP2C De novo VOUS ADHD-Inattentive sub-type, slow learner
Case Gh 222710 M delj 10p15.3 67,632 DIP2C De novo VOUS Normal learning profile
del 7q36.2 14,653 DPP6 Paternal VOUS
Inherited: DECIPHER syndromes /cytogenetic chromosomal anomalies
Case Gh 222710 M dup 22q11.21 2,548,820 45 genes Paternal Likely pathogenicn Normal learning profile
Case Hh 216192 M del 17p12 1,395,494 PMP22 + 8 genes Paternal Pathogenico N/A
Inherited: CNVs impacting neurodevelopmental or muscular function genes
Case Ih 219594 M del 3p26.3 1,027,287 CNTN6, CNTN4, CNTN4-AS2 Paternal VOUS Normal learning profile
Case Jf 198195 M dup 8p23.1, 8p23.2 973,229 MCPH1 + 10 genes Maternal VOUS Normal intellectual development
Case Kh 214281 F dup 5q11.2 504,651 HSPB3, ARL15 Maternal VOUS Normal learning profile
Case Lf 216197 F dup 16p13.2 370,593 ABAT, USP7 + 4 genes Maternal VOUS Language-based learning disability
Case Mf 217737 M dup 8q24.3 255,856 KCNK9 Maternal VOUSp Language-based learning disability
dup 7q36.3 251,267 NCAPG2, ESYT2 Maternal VOUS
Case Nf 247947 F dup 1q23.2 196,398 KCNJ10, KCNJ9 + 5 genes Maternal VOUS Normal intellectual development
Case Of 217932 M del 3q26.31 176,370 NAALADL2 Maternal VOUS N/A
Case Pf 208289 F dup 22q11.21 162,405 DGCR2, DGCR14 + 4 genes Maternal VOUS ASD, ADHD
Case Qf 221713 F del 7q35 114,399 CNTNAP2 Maternal VOUS Normal learning profile
Case Rf 208341 F del 5p15.31 77,527 SEMA5A Maternal VOUS Language-based learning disability
Case Sf 234267 F dup 9q33.1 40,814 ASTN2 Paternal VOUSq Normal intellectual development
Case Th 239838 F del 22q12.3 34,122 RFPL2, SLC5A4 Paternal VOUS Normal intellectual development
Case Uh 208290 F del 18p11.31 25,582 DLGAP1 Maternal VOUS Normal learning profile
Case Vh 199743 F dup 16q24.3 24,064 ZNF778 Maternal VOUS Intellectual disability
Case Wf 209038 F dup 17p11.2 16,602 MYO15A Paternal VOUSr Normal intellectual development
CNV, copy-number variant; CP, cerebral palsy; del, deletion; dup, duplication; F, female; M, male; VOUS, variant of uncertain significance with respect to CP and comorbid features.
aRare CNVs for all individuals are provided in Supplementary Table S2. bEach CNV validated by SYBR Green–based real-time quantitative PCR, or TaqMan assay, or droplet digital PCR (ddPCR) with TaqMan assay (see
Supplementary Table S3). cThe actual coordinates are in Supplementary Table S2. dThe probabilities of truncating loss-of-function intolerance (pLI) for genes impacted by CNVs are shown in Supplementary Table S5.
eRefer to Supplementary Table S1 for detailed clinical information. fRight hemiplegia CP. gKlinefelter syndrome (47,XXY). hLeft hemiplegia CP. iTurner syndrome. jMosaic variants validated using ddPCR with TaqMan assay
(see Supplementary Information for additional information). kMale carrier of this recurrent deletion is associated with ichthyosis. No phenotype in females. lPartial duplication of DMD may or may not affect expression.
mGRIK2 associated with autosomal recessive mental retardation. Deletion of one copy not expected to be pathogenic. n22q11.2 duplication syndrome. oRecurrent deletion is associated with hereditary neuropathy with
liability to pressure palsies syndrome. pPartial duplication of KCNK9 may or may not affect expression of this gene. qIntragenic duplication may disrupt protein. rMYO15A is associated with autosomal recessive deafness.
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Stratifying cases into two groups
We stratified cases into two categories: those with identified
CNV risk (n= 23) and those without a CNV risk (n= 74)
(Table 2). We found that there were significantly more
females in the CNV group (P= 0.006). Among potential risk
factors for CP, there was a significant difference in gestational
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Figure 2 Critical exons in genes expressed prenatally are significantly impacted by rare CNVs in 16 different brain regions. The P value is
corrected using the Benjamini-Hochberg method. AMY, amygdaloid complex; CBC, cerebellar cortex; V1C, primary visual cortex; STC, posterior (caudal)
superior temporal cortex; IPC, posterior inferior parietal cortex; A1C, primary auditory cortex; S1C, primary somatosensory cortex; M1C, primary motor
cortex; STR, striatum; DFC, dorsolateral prefrontal cortex; MFC, medial prefrontal cortex; VFC, ventrolateral prefrontal cortex; OFC, orbital frontal cortex;
MD, mediodorsal nucleus of thalamus; ITC, inferolateral temporal cortex; HIP, hippocampus.
Case D
de novo 1.1 Mb dup(18p11.23-18p11.31)
de novo 309.4 kb dup(Xp21.2)
Case C
de novo 1.7 Mb del(Xp22.31)
76.8 kb dup(11q24.1)
39.6 kb dup(3q11.2)
76.8 kb dup(11q24.1)
39.6 kb dup(3q11.2)
Case G
de novo 67.6 kb del(DIP2C)
2.5 Mb, dup(22q11.2)
14.6 kb, del(DPP6)
COL4A2 (p.Gly974Glu)
2.5 Mb, dup(22q11.2)
14.6 kb,del(DPP6) COL4A2 (p.Gly974Glu)
Figure 1 Pedigrees of selected families (cases C, D, and G) with multiple variants.
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term between the groups (P= 0.02), with the CNV group
having a lower rate of prematurity. Levels of factors such as
advanced maternal age, use of in vitro fertilization, the
presence of congenital malformations, and markers of
childbirth complications, among others, were not found to
be significantly different between the two groups.
Notable case findings
De novo CNVs and CNVs known to be associated with
DECIPHER syndrome loci
Case A has sex chromosome aneuploidy with a diagnosis of
Klinefelter syndrome (47, XXY). Neurological disorders such
as CP, ADHD, epilepsy, and delayed motor milestones have
been reported in some patients with Klinefelter syndrome.21
Case B carries a complex rearrangement: a mosaic duplica-
tion (70Mb) spanning chromosome Xp and the centromere
side of Xq. She also has an 84.9Mb deletion of distal Xq
starting from the same breakpoint as where the duplication
ends (Table 1; Supplementary Figure S2). The retained copy
of the q arm is maternal in origin. This might reflect an
iso-dicentric chromosome X with a terminal deletion of
paternal origin, but confirmation by karyotype is needed.
Delays in gross motor milestones and reduced general muscle
tone and strength are reported in cases with X-chromosome
monosomy.21 Since both deletions and duplications of
chromosome X are associated with delayed motor functions,
we consider whether CP in this patient may be explained by
these chromosomal anomalies. Her intellectual ability was
unknown. Her mother’s maternal age was advanced.
Case C carries one de novo and two maternally inherited
CNVs (Figure 1). The de novo variant is a 1.7Mb deletion on
Xp, impacting five genes including STS, which is associated
with steroid sulfatase deficiency (Supplementary Figure S3).
Others studied a link between haploinsufficiency of STS
and neurodevelopmental disorders, including intellectual
disability and autism in a girl.22 Her inherited variants
include a 39.6 kb duplication impacting EPHA6, a gene impli-
cated in autism (Supplementary Figure S4) and a 76.8 kb
Table 2 Characteristics of patient groups with and without CNVs
CNVa Non-CNVa Test statistic Significance
Participant characteristics
Age (years) %x (s) 8.35 (4.84) 9.67 (4.90) −1.1b 0.26
Sex
Male 8 (34.8%) 51 (68.9%) 8.6b 0.006
Female 15 (65.2%) 23 (31.1%)
Hemiplegia n (%)
Left 13 (56.5%) 37 (51.4%)
Right 10 (43.5%) 35 (48.6%), M= 2 1.1b 0.58
Neuroimaging n (%)
MCA 7 (30.4%) 24 (32.4%)
PVI 10 (43.5%) 30 (40.5%) 2.9b 0.24
Otherc 1 (4.34%) 4 (5.4%)
Not available 5 (21.7%) 16 (21.6%)
Quality of Upper Extremity Skills Test score %x(s) 63.24 (27.1) 63.79 (30.5) −0.1d 0.94
Full Scale IQ percentile scoree %x(s) 35.47 (26.9) 46.08 (31.1) −1.2d 0.28
Potential risk factors for CP
Advanced maternal age (≥35 years) n (%) 9 (39.1%) 18 (25.7%), M= 4 1.5b 0.29
Family history of genetic risk factorsf n (%) 4 (17.4%) 15 (20.8%), M= 2 0.8b 0.68
Use of in vitro fertilization n (%) 1 (4.3%) 3 (40.5%) 1.1b 0.59
Gestation n (%)
Prematurity (o37 weeks) 1 (4.3%) 20 (27.0%)
Term (≥37 weeks) 21 (91.3%) 47 (63.5%) 5.9b 0.02
Unavailable 1 (4.3%) 7 (9.5%)
Small or large birth weight for gestational ageg n (%) 6 (27.3%), M= 1 10 (15.4%), M= 9 1.6b 0.22
Congenital malformations n (%) 6 (26.1%) 14 (18.9%) 0.6b 0.56
Birth process complicationsh n (%) 14 (60.9%) 46 (63%), M= 1 0.03b 0.52
The sample had the following functional classification levels: Gross Motor Functional Classification level I (85.5%), II (10.5%), and III (3.9%); Manual Abilities Classifica-
tion System level I (50%), II (39.7%), III (8.6%), and IV (1.7%); and Communication Function Classification System level I (75.5%), II (13.8%), III (5.2%), and IV (2.1%).
CNV, copy-number variation; M, missing data number per cell; MCA, middle cerebral artery; PVI, periventricular infarct; s, standard deviation; %x, mean.
aNumbers of individuals in the CNV and non-CNV groups are 23 and 74, respectively. bChi-square. cOther: for example, non-middle cerebral artery stroke, brain mal-
formation. dt-test. eIQ testing was assessed only in children > 4 years old. f”Family history of genetic risk factors” was defined as participants having a1st- or 2nd-degree
relative with CP, early stroke or heart attack (o60 years old), or consanguinity. Consanguinity is defined as a hereditary relationship between biological parents or
grandparents of the index child that is the result of having a common parent or other ancestor. gSmall birth weight for gestational age ≤ 10th percentile; high birth
weight for gestational age ≥ 97th percentile. h”Birth process complications” was defined as having undergone an emergency cesarean section, had an Apgar score o6
at five minutes, undergone resuscitation at birth, had umbilical cord blood pH o7.35, or seizures in the first 24 to 72 h of life, and/or neonatal encephalopathy.
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duplication impacting SCN3B (Supplementary Figure S5). The
latter gene encodes a member of the sodium channel subunit in
neurons and muscle cells; mutations in such genes are involved
in epilepsy,23 a comorbidity of CP. This case has a family
history of CP and early stroke.
Case D has a language-based learning disability, is function-
ing at a GMFCS level of I, and carries two de novo dupli-
cations (Table 1 and Supplementary Table S1; Figure 1). The
first CNV is a 309 kb duplication impacting the first 15 exons
of the DMD gene (all exons for five isoforms), and a single
exon of the FTHL17 gene (Supplementary Figure S6).
Duplication of DMD was reported in a female with spastic right
hemiplegia.4 The second CNV is a 1.15Mb duplication of
18p11.23–18p11.31, impacting three genes: LAMA1, PTPRM,
and LRRC30 (Supplementary Figure S7). Protein-truncating
variants in the LAMA1 gene have been linked to congenital
muscular dystrophy, myopia, and retinal dystrophy.24
Case E, who has normal intellectual development, harbors a
475.1 kb de novo CNV deletion impacting GRIK2 (Supple-
mentary Figure S8 and Supplementary Table S1), which
belongs to the kainate family of glutamate receptors.
Haploinsufficiency of members of this family can cause
intellectual disability.25 She also carries a de novo damaging
point mutation in NOVA1, which may contribute to her
phenotype (OMIM 615683).
Cases F and G each have a de novo 67.6 kb deletion
impacting at least two exons in the DIP2C gene (Figure 1).
Case F has ADHD (inattentive subtype), is a slow learner, and
has a proximal middle cerebral artery infarction. Case G has a
family history of CP (mother and maternal second cousin) and
he had seizures on his third day of life. No imaging was
available for this case. Genetic variants of DIP2A, DIP2B, and
DIP2C have a possible role in developmental dyslexia,
intellectual disability, and developmental delay.26 Among
ASD cases one inherited frameshift and two de novo
mutations in the DIP2C gene have been reported.27,28 Case G
also carries two paternally inherited CNVs and a point
mutation in COL4A2, but none in DIP2C (Figure 1). One
CNV is a 2.5Mb duplication reciprocal to the 22q11.2 deletion
syndrome locus, which is sometimes associated with ASD.14
This patient also carries a 14.6 kb deletion impacting the DPP6
gene (Supplementary Figure S9). This gene has been
associated with a number of human central nervous system
disorders, including ASD, intellectual disability, and spinal
muscular atrophy.29 This patient also carries a heterozygous
point mutation inherited from his mother in the COL4A2 gene
(c.2921G>A; p.Gly974Glu; identified by gene-panel testing by
clinical geneticists at the Hospital for Sick Children; and
confirmed for this study with exome and Sanger sequencing).
Mutations in this gene, which is expressed in the basement
membrane during early development, have been reported in
patients with muscular cramps, cerebral small-vessel disease,
and hemorrhagic stroke (OMIM 120090).
Case H is functioning at a GMFCS level I and carries
a 1.4 Mb paternally inherited deletion in 17p12, a region
associated with hereditary neuropathy with liability to
pressure palsies syndrome, characterized by muscle weakness
(OMIM 162500).
Inherited CNVs impacting neurodevelopmental or muscular
risk genes
In addition to two CNVs associated with DECIPHER
syndrome loci discussed above (Cases G and H), we observed
19 inherited CNVs from 18 patients (18/97= 18.6%). We
describe three of these here, and the rest in the Supple-
mentary Information.
Case I, who has a normal intellectual profile, carries a
1.03 Mb paternally inherited deletion impacting the first exon
of the CNTN4 gene and all except the first two exons of the
CNTN6 gene (Supplementary Figure S10). These two genes
belong to the family of contactin genes (CNTNs) with a role
in formation of axon connections in the developing
nervous system. Deletions of CNTNs have been linked to
hypotonia, psychomotor retardation, ASD, intellectual
disability, developmental delay, microcephaly, and other
neurodevelopmental disorders.30
Case L has a language-based learning disability. She carries a
maternally inherited 370.6 kb duplication impacting ABAT,
USP7, and four other genes (Supplementary Figure S11). De
novo CNVs, including duplications, impacting the USP7 gene,
are implicated in ASD and schizophrenia.31 The ABAT
deficiency phenotype includes psychomotor retardation and
seizures. Single nucleotide variants in the ABAT gene, probably
disrupting its protein function, may have a link to autism.32
Case Q, who has a normal developmental profile, carries a
maternally inherited 114.4 kb deletion impacting exons 8 and
9 of the CNTNAP2 gene (Supplementary Figure S12), which
encodes a member of the neurexin family with function in
the nervous system. Deletions, including only a single exon of
this gene, have been implicated in dyslexia, apraxia, language
impairment, motor regression, and intellectual disability.33
This case also carries a paternally inherited potentially
damaging missense SNV in COL4A2.
DISCUSSION
We found de novo CNVs in 7.2% of cases in this well-defined
collection of individuals with hemiplegic CP. This was
comparable to the 7% we previously reported in a cohort of
individuals with CP from all subtypes,4 but higher than the
de novo CNV rate in other neurodevelopmental disorders,
including idiopathic ASD, ADHD, ID, and schizophrenia
(reviewed by Oskoui et al.4). However, in a cohort of CP
cases from Israel, 13% had de novo CNVs.8 Taken together,
these findings suggest that de novo CNVs may be contributing
to the etiology of various subtypes of CP, including hemiplegia.
The contribution of rare inherited CNVs to the etiology of
hemiplegia has been reported previously, but only in mixed
cohorts, rather than a purely hemiplegic cohort, as reported
here. Our group identified two inherited duplications in cases
with spastic right hemiplegia,4 and McMichael et al.10
identified rare inherited CNVs in cases diagnosed with
hemiplegia. Here, in 18.6% (18/97) of our subjects, we found
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rare inherited CNVs (63% duplications), impacting genes
expressed in the brain or congruent with genomic disorders.
For example, brain-expressed genes in the neurexin or
contactin, and immunoglobulin gene families, (e.g.,
CNTNAP2, CNTN4, CNTN6), or genes encoding members
of potassium or sodium channels (i.e., KCNK9, KCNJ9,
KCNJ10, and SCN3B), were perturbed in our hemiplegic CP
cohort. Alterations of these genes are risk factors for other
neurodevelopmental disorders. For inherited variants, many
factors may explain the phenotype discordance between child
and parent, including variable expressivity, incomplete
penetrance, and epigenetic modification of gene expression.
Of those genes impacted by the de novo and inherited CNVs
in this study, GRIK2, KCNJ9, KCNJ10, GLGAP1, PTPRM, and
DPP6 are clustered together in a protein interaction network
(Supplementary Figure S13).
Inflammation, including chorioamnionitis and congenital
infections, is an established risk factor for all CP subtypes
including hemiplegia, owing possibly to abnormalities in the
inflammatory response system.34 An earlier study established
a link between a SNP (rs1800795) in interleukin-6 (IL-6) and
CP.34 However, we found no CNVs impacting genes involved
in the inflammatory response, including those highlighted in
two population-based studies.35,36
The enrichment of brain-expressed critical exons impacted
by CNVs in our cases (as seen in other neurodevelopmental
disorders such as ASD16) may explain factors contributing
to the etiology of hemiplegia as well as the associated neuro-
developmental comorbidities. The primary motor cortex and
cerebral cortex may be particularly relevant to core phenotypes
of the hemiplegic CP. Although the scores for the pLI burden
in our cases were not significantly elevated, the higher mean
score may provide additional evidence that perturbed genes
would be a contributory factor in the etiology of CP.
Among individuals with CP including hemiplegia, about
20% have neurodevelopmental disorders and 9% have ASD.37
Multiple de novo CNVs impacting genes implicated in
ASD were found in our CP cases. For example, cases E, F,
and G have de novo deletions impacting exons of GRIK2
and DIP2C, with a pLI score corresponding to be highly
constrained (pLI> 0.9; Table 1 and Supplementary Table S5).
We also found rare inherited exonic deletions and duplications
impacting other ASD risk genes, e.g., KCNK9, CNTN6,
CNTN4, ASTN2, and MCPH1, in our CP cases (Table 1).
In our CNV-positive cases, only case P, with a 22q11.21
duplication, has ASD (as well as ADHD). We also uncovered
CNVs at three genomic disorder loci: a de novo deletion of
Xp22.31associated with steroid sulfatase deficiency, a 22q11.21
duplication, and a 17p12 deletion (both inherited).
In our sample we found that the CNV group had propor-
tionally more females and lower rates of prematurity than the
non-CNV group. Clinically, CP cases are more common in
males than females (with a ratio of 1.3, or 1.5 in the current
study) although the exact risk mechanism has not been
well established. However, as with autism,14 females were
represented more frequently in the CNV-positive cases
(P= 0.006). Prematurity is also a significant CP risk factor,
increasing the chance of developing CP 100-fold.38 However,
in this study, term gestation was more common in the CNV-
positive cases. The increased prevalence of females and
children born at term in the CNV-positive group could be
explained by the presence of a CNV itself being a risk factor
that contributes to the etiology of hemiplegic CP. This could
also explain the overrepresentation of other risk factors, such
as higher rates of males and prematurity (P= 0.02), in the
non-CNV group (Table 2).
We identified potentially damaging point mutations in
COL4A2, a gene associated with hemorrhagic stroke, in cases
G and Q (OMIM 120090), thus contributing to the under-
standing of stroke in the etiology of hemiplegic CP. Birth
asphyxia (neonatal encephalopathy) has been associated with
CP in 10%–20% of individuals.1 Genetic variations could also
underlie vulnerabilities that lead to birth asphyxia.39 The
presence of potentially harmful CNVs in 23.7% (23/97) of our
cohort may provide further evidence for this hypothesis,
although we did not identify a difference in childbirth compli-
cations in the CNV, compared to the non-CNV, group.38
However, the CP risk factors of advanced maternal age, use of
in vitro fertilization, and the presence of congenital malforma-
tions were not significantly different between these two groups.
Our results show that hemiplegic CP can be associated with
de novo or rare inherited CNVs. The presence of de novo
CNVs and those involving well-defined genomic disorders
among our cohort suggests the benefit of genomic testing for
diagnostic purposes in hemiplegic CP. DOPA-responsive
dystonia and hereditary spastic paraplegia (HSP) can present
in asymmetric neurologic presentations with one side more
involved in the early stages, and are conditions with identified
genetic mutations in the GCH1 and ATL1 genes, respectively,
but may be misdiagnosed as CP.40 The distinction is
important, as DOPA-responsive dystonia can be treated with
medications such as levodopa, and the clinical trajectory of
HSP is different from that of CP as the neurologic symptoms
progress. Therefore, genetic testing, particularly whole-
genome sequencing, which has the potential for detecting
CNVs and smaller variants, should be considered as part of
the diagnostic assessment of an individual presenting with CP
symptoms, for ruling out neurologic disorders with similar
phenotypes, or garnering a better understanding of the
etiology of CP for that particular individual.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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